The overall objective will be to evaluate clinical predictors of outcomes in patients who undergo endovenous sclerotherapy for the treatment of varicose veins.
A prospective cohort study of patients who undergo endovenous sclerotherapy over 2 years. There are no deviations in usual clinical assessment and care of patients seeking varicose vein treatment. The purpose of this protocol is only to collect clinical and biomarker information related to this standard treatment.
Study Type
OBSERVATIONAL
Enrollment
100
University of Oklahoma Health Sciences Center campus at the OU Vascular Center
Oklahoma City, Oklahoma, United States
Frequency of obliteratin (total or partial) of injected varicosity.
Time frame: assessment will be at 1, 12, and 26 weeks.
Improvement in venous stasis symptoms.
Time frame: assessment will be at 1, 12, and 26 weeks
Change in quality of life.
Time frame: assessment will be at 1, 12, and 26 weeks
Associations between clinical outcomes and biomarkers.
Time frame: assessment will be at 1, 12, and 26 weeks
Recurrence of varicosities.
Time frame: assessment will be at 1, 12, and 26 weeks
Adverse events reported following procedure.
Time frame: assessment will be at 1, 12, and 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.